

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-16 (Canceled).

Claim 17 (Currently amended). Use of a halogenated xanthene comprising:

topically administering a therapeutically effective amount of the halogenated xanthene as the photoactive agent, present in a pharmaceutical composition in a concentration of ~~greater than~~ approximately 1 micromolar ~~0.0001% w/v~~ to less than approximately 0.1% ~~1%~~ w/v, to or proximate to human or animal tissue and photoactivating the halogenated xanthene present within or proximate to said tissue within 1 hour or less following administration, wherein said halogenated xanthene is a compound selected from the group consisting of ~~the dibasic salts of~~ disodium Erythrosin B; disodium Phloxine B; disodium Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claim 18 (Previously presented). The use of Claim 17 wherein said halogenated xanthene is Rose Bengal.

Claim 19 (Previously presented). The use of Claim 17 wherein said halogenated xanthene is photoactivated with light having a wavelength of between approximately 500 nm and 600 nm.

Claims 20-31 (Canceled).

Claim 32 (Currently amended). A method of treating diseased tissue comprising:

topically applying a photodynamic medicament consisting of a halogenated xanthene as the photoactive component to or proximate to diseased human or animal tissue, wherein said halogenated xanthene is a compound selected from the group consisting of ~~the dibasic salts of~~ disodium Erythrosin B; disodium Phloxine B; disodium Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, said halogenated xanthene being present in said medicament at a concentration of ~~greater than~~ approximately 1 micromolar ~~0.0001% w/v~~ to less than approximately 0.1% ~~1%~~ w/v; and

illuminating said human or animal tissue with light within 1 hour or less following said applying to photoactivate said halogenated xanthene present within or proximate to said tissue.

Claim 33 (Previously presented). The method of Claim 32 wherein said diseased human or animal tissue comprises the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tracts and related organs, other internal and external tissue surfaces, tissue surfaces exposed during surgery, and tissue with microbial or parasitic infection.

Claim 34 (Previously presented). The method of Claim 32 wherein said step of illuminating uses light having a wavelength of between approximately 500 nm and 600 nm.

Claims 35-37 (Canceled).